If you would like more information about the profile please click Request More Information . You will be directed to a new page where you will need to provide some information about yourself/your business cooperation needs and submit your expression of interest in the profile . A Network Partner will then contact you to discuss your interest in greater detail.
A UK company is offering a mass testing system for Covid-19 using advanced laser techniques (Diffractive Phase Interferometry, DPI) on a drop of blood from the patient. The company is working with a UAE company and are seeking medical testing laboratories whose research is of viral infection control, to help qualify and quantify this testing method in the UK and Europe, via technical cooperation agreement.
The UK company working with a UAE developer is offering a means to “mass test” and perform individual testing for viral infection using advanced laser techniques (DPI) on a drop of blood from the patient. The DPI method is a non-evasive testing system, that is confined to a portable unit, low technical knowledge and medical training to operate the unit. It does not rely on a laboratory to analyse the results. The unit has a screen to show the image from the DPI testing. This allows the product to be used by medical staff for close analysis, at the same time the cloud-based AI will determine the results. The system is currently used as the main mass testing for all boarders of the UAE. It has been sold to 26 other mid and far east countries. The company is seeking medical testing laboratories working in viral control, vaccination trails and medical screening, to use the product and participate in the control and monitoring of patients, with the ability to test and monitor with the need for a laboratory for clinical trials. The company is seeking medical testing laboratories whose key research is of viral infection control, to help qualify and quantify this testing method in the UK and Europe, via technical cooperation agreement.
The DPI method of testing using a unique approach to the analysis of the surface of the red blood cells, in simple terms, the red blood cells are round in shape, this gives a “signature” image, when the cells are infected, the virus attaches itself to the outside of the red blood cell, which creates a unique indentation, for each viral infection the deformation is unique, and image from the DPI clearly shows an infection. So that the user does not have to be highly trained, and to keep the viral profiling up-to-date, the results from the DPI test is sent to a cloud-based AI for analysis. The total time can be a few seconds. The AI has been accumulating data for the past 10 months. It is worth noting that medicines can have an effect on the shape of the cells surface, and the AI can account for this. Is it also a point of interest for viral drug trails, where at each stage, the blood can be tested to see the effect of the forced infection, by showing the cell structure before the trials, and at each stage during the day and night without the need for a laboratory. The AI can also be “taught” to detect a range of viruses, so a screening for contagious infections can be achieved. Also, the DPI can detect the infection of the blood, whether the patient is aware of it or not, even carriers will show the infection. It will detect the infection at any stage where the body has been infected.
Patents not yet applied for.
Type: Industry Activity: Medical research laboratories Specific role of partner sought: The testing of a new mass testing system for Covid-19